| __timestamp | Incyte Corporation | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 72471000 |
| Thursday, January 1, 2015 | 196614000 | 89204000 |
| Friday, January 1, 2016 | 303251000 | 106010000 |
| Sunday, January 1, 2017 | 366406000 | 137905000 |
| Monday, January 1, 2018 | 434407000 | 159888000 |
| Tuesday, January 1, 2019 | 468711000 | 158425000 |
| Wednesday, January 1, 2020 | 516922000 | 200677000 |
| Friday, January 1, 2021 | 739560000 | 304759000 |
| Saturday, January 1, 2022 | 1002140000 | 377221000 |
| Sunday, January 1, 2023 | 1161300000 | 336361000 |
| Monday, January 1, 2024 | 1242157000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Incyte Corporation and Supernus Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Incyte's SG&A expenses surged by approximately 600%, reflecting its aggressive growth strategy. In contrast, Supernus exhibited a more moderate increase of around 360% during the same period.
Incyte's spending peaked in 2023, reaching nearly three times that of Supernus, indicating a robust expansion phase. This trend suggests Incyte's commitment to scaling operations and enhancing market presence. Meanwhile, Supernus's steady rise in expenses highlights a more conservative approach, focusing on sustainable growth.
These patterns underscore the diverse strategies within the pharmaceutical sector, where companies balance between rapid expansion and steady growth to maintain competitive advantage.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Incyte Corporation
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
GSK plc or Incyte Corporation: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Incyte Corporation vs Insmed Incorporated
Selling, General, and Administrative Costs: Incyte Corporation vs Verona Pharma plc
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bausch Health Companies Inc. or Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Wave Life Sciences Ltd.
Supernus Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends